Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea FDA To Approve First Stem Cell Therapy For Myocardial Infarction

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In what might be marked as the world's first approved stem-cell medication, Korea FDA plans to approve in early July Hearticellgram-AMI, a stem cell therapy for acute myocardial infarction, developed by Korean bioventure FCB-Pharmicell

You may also be interested in...



2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?

SEOUL - Pricing pressure and increased government oversight of irregular business activities could prompt Korean pharmaceutical companies to focus on new growth strategies for 2011 such as cooperative deals with multinational companies and exports into new emerging markets like China, according to Korean analysts

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest News
See All
UsernamePublicRestriction

Register

SC078378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel